Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | GLP1R | P43220 | 8/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | MMP14 | P50281 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CCKBR | P32239 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25845185 | 0.91 | AKT1 (0.35) | AKT1 | |
| SCHEMBL25840353 | 0.88 | GLP1R (0.42) | AKT1GLP1RKMT2AMEN1 | |
| SCHEMBL27382530 | 0.88 | GLP1R (0.43) | AKT1GLP1RKMT2AMEN1 | |
| SCHEMBL27382245 | 0.83 | GLP1R (0.34) | AKT1GLP1R | |
| SCHEMBL25839706 | 0.82 | AKT1 (0.33) | AKT1KMT2AMEN1 | |
| SCHEMBL25840350 | 0.81 | GLP1R (0.33) | GLP1R | |
| SCHEMBL25857086 | 0.80 | — | — | |
| SCHEMBL24340762 | 0.78 | MGLL (0.32) | AKT1KMT2AMEN1 | |
| SCHEMBL25839762 | 0.78 | POLB (0.39) | AKT1KMT2AGAAMEN1POLB | |
| SCHEMBL18544643 | 0.78 | AKT1 (0.31) | AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265430-A1 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265430-A1 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | ZFX, DDX39B, DDX21 | AKT1 4345/4885GLP1R 4312/4885MMP2 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.